Business Model: Manufacturing / OEM, B2B
Category: Biotechnology, Health Care, Medical Device, Cardiology
Geographic Markets: Europe, North America, Israel
V-Wave Ltd. is a privately held company with offices in Israel and the US.
The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF). As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment.
V-Wave has developed a proprietary interatrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life. The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.
V-Wave makes money by selling implantable devices for treating patients with chronic Heart Failure.
The Due Diligence Report for V-Wave, prepared with crowd analysis and predictive algorithms, perfect for investment assessment, research and general in depth analysis.
Pura Vida Investments
Israel Secondary Fund
Aperture Venture Partners
Johnson & Johnson Innovation
V-Wave began clinical trials in 2013 in Israel, the United States, and Europe. The V-Wave shunt is currently under investigation in multiple clinical trials in North America, Europe, and Israel.
A key component of V-Wave’s team are the five medical doctors on board with decades of experience in cardiology.
V-Wave’s product could potentially disrupt the market by treating an increasingly widespread medical problem.
Occlutech, is a rapidly expanding European hi-tech company specializing in developing and manufacturing cardiac occlusion devices and other vascular implants.
Corvia Medical a medical device company, focuses on developing structural heart devices for the treatment of heart failure.
Confidentiality: The Elephant, the online trading arena, provides a balance between the private shareholders (employees and former employees) need to protect its confidential information and the investor’s need for the transparency necessary to make an informed investment decision.
Content Sources: All the information presented above was retrieved from public sources (media, company website, data from the registrar of private shareholder, etc.).
Responsibility: The Elephant does not accept any responsibility or liability for the accuracy, content and reliability of this information.